Delaware
|
333-82900
|
94-3018487
|
||
(State or other jurisdiction of incorporation or organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
[ ]
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
[ ]
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
[ ]
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
[ ]
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
THERMOGENESIS CORP.,
|
|||
a Delaware Corporation
|
|||
/s/ Matthew T. Plavan
|
|||
Matthew T. Plavan,
|
|||
Chief Executive Officer and Chief Financial Officer
|
|||
Exhibit No.
|
Description
|
|||
99.1
|
Press release dated September 20, 2012, titled “ThermoGenesis Reports Fourth Quarter and Full Year Fiscal 2012 Results; Company Lowers Fourth Quarter Loss and Realizes Major Milestones in Growth Strategy.”
|
|||
Dial-in (U.S.):
|
1-800-860-2442
|
||
Dial-in (Internationally):
|
1-412-858-4600
|
||
Conference Name:
|
“ThermoGenesis”
|
Access number (U.S.):
|
1-877-344-7529
|
||
Access number (Internationally)
|
1-412-317-0088
|
||
Conference ID#:
|
385107
|
·
|
The BioArchive® System, an automated cryogenic device, used by cord blood stem cell banks in more than 30 countries for cryopreserving and archiving cord blood stem cell units for transplant.
|
·
|
AXP® AutoXpress® Platform (AXP), a proprietary family of automated devices that includes the AXP and the MXP® MarrowXpress® and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood. The MXP is used for the preparation of cell concentrates, including stem cells from bone marrow aspirates in the laboratory setting.
|
·
|
The Res-Q® 60 BMC/PRP (Res-Q), a point-of-care system designed for the preparation of cell concentrates, including stem cells, from bone marrow aspirates and whole blood for platelet rich plasma (PRP).
|
June 30,
2012
|
June 30,
2011
|
|||
ASSETS
|
||||
Current assets:
|
||||
Cash and cash equivalents
|
$7,879,000
|
$12,309,000
|
||
Accounts receivable, net
|
4,558,000
|
3,963,000
|
||
Inventories
|
6,290,000
|
6,348,000
|
||
Other current assets
|
338,000
|
420,000
|
||
Total current assets
|
19,065,000
|
23,040,000
|
||
Equipment, net
|
1,652,000
|
1,310,000
|
||
Intangible asset
|
315,000
|
--
|
||
Other assets
|
48,000
|
49,000
|
||
$21,080,000
|
$24,399,000
|
|||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||
Current liabilities:
|
||||
Accounts payable
|
$2,772,000
|
$1,791,000
|
||
Other current liabilities
|
2,259,000
|
2,273,000
|
||
Total current liabilities
|
5,031,000
|
4,064,000
|
||
Long-term liabilities
|
151,000
|
242,000
|
||
Stockholders’ equity
|
15,898,000
|
20,093,000
|
||
$21,080,000
|
$24,399,000
|
Three Months Ended
June 30,
|
Year Ended
June 30,
|
||||||
2012
|
2011
|
2012
|
2011
|
||||
Net revenues
|
$4,481,000
|
$5,378,000
|
$19,023,000
|
$23,400,000
|
|||
Cost of revenues
|
3,032,000
|
3,512,000
|
12,690,000
|
14,563,000
|
|||
Gross profit
|
1,449,000
|
1,866,000
|
6,333,000
|
8,837,000
|
|||
Expenses:
|
|||||||
Selling, general and administrative
|
1,692,000
|
2,245,000
|
7,983,000
|
8,669,000
|
|||
Research and development
|
810,000
|
789,000
|
3,729,000
|
3,003,000
|
|||
Total operating expenses
|
2,502,000
|
3,034,000
|
11,712,000
|
11,672,000
|
|||
Interest and other income, net
|
315,000
|
--
|
393,000
|
268,000
|
|||
Net loss
|
($738,000)
|
($1,168,000)
|
($4,986,000)
|
($2,567,000)
|
|||
Basic and diluted net loss per common share
|
($0.04)
|
($0.07)
|
($0.30)
|
($0.17)
|
|||
Shares used in computing per share data
|
16,408,599
|
16,346,366
|
16,389,008
|
14,816,163
|
Year Ended
June 30,
|
|||
2012
|
2011
|
||
Cash flows from operating activities:
|
|||
Net loss
|
($4,986,000)
|
($2,567,000)
|
|
Adjustments to reconcile net loss to net cash used
in operating activities:
|
|||
Depreciation and amortization
|
604,000
|
466,000
|
|
Stock based compensation expense
|
791,000
|
960,000
|
|
Loss on sale/retirement of equipment
|
17,000
|
13,000
|
|
Loss on impairment of equipment
|
--
|
65,000
|
|
Net change in operating assets and liabilities:
|
|||
Accounts receivable, net
|
(655,000)
|
2,132,000
|
|
Inventories
|
120,000
|
(1,338,000)
|
|
Prepaid expenses and other current assets
|
(38,000)
|
1,000
|
|
Other assets
|
1,000
|
119,000
|
|
Accounts payable
|
696,000
|
(592,000)
|
|
Accrued payroll and related expenses
|
223,000
|
75,000
|
|
Deferred revenue
|
2,000
|
(604,000)
|
|
Other liabilities
|
(660,000)
|
(822,000)
|
|
Net cash used in operating activities
|
(3,885,000)
|
(2,092,000)
|
|
Cash flows from investing activities:
|
|||
Capital expenditures
|
(545,000)
|
(266,000)
|
|
Proceeds from sale of equipment
|
--
|
17,000
|
|
Net cash (used in)/provided by investing activities:
|
(545,000)
|
(249,000)
|
|
Cash flows from financing activities:
|
|||
Exercise of stock options
|
--
|
7,000
|
|
Issuance of common stock
|
--
|
3,914,000
|
|
Payments on capital lease obligations
|
--
|
(2,000)
|
|
Net cash provided by/(used in) financing activities
|
--
|
3,919,000
|
|
Net increase/(decrease) in cash and cash equivalents
|
(4,430,000)
|
1,578,000
|
|
Cash and cash equivalents at beginning of period
|
12,309,000
|
10,731,000
|
|
Cash and cash equivalents at end of period
|
$7,879,000
|
$12,309,000
|